Patents by Inventor Ronald B. Luftig

Ronald B. Luftig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor
    Patent number: 6557296
    Abstract: This invention is directed toward mutated DNA, proteins, or protein fragments and particles from the L-2 cell line. The invention is also directed to diagnostic, prophylactic and therapeutic methods of making and using the DNA, proteins and particles.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: May 6, 2003
    Assignee: The Immune Response Corporation
    Inventor: Ronald B. Luftig
  • Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor
    Publication number: 20020061313
    Abstract: This invention is directed toward mutated DNA, proteins, or protein fragments and particles from the L-2 cell line. The invention is also directed to diagnostic, prophylactic and therapeutic methods of making and using the DNA, proteins and particles.
    Type: Application
    Filed: July 30, 2001
    Publication date: May 23, 2002
    Applicant: The Board of Supervisors of Louisiana State University
    Inventor: Ronald B. Luftig
  • Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor
    Patent number: 6328976
    Abstract: This invention is directed toward mutated DNA, proteins, or protein fragments and particles from the L-2 cell line. The invention is also directed to diagnostic, prophylactic and therapeutic methods of making and using the DNA, proteins and particles.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: December 11, 2001
    Assignee: Immune Response Corporation
    Inventor: Ronald B. Luftig
  • Detection of human adenovirus
    Patent number: 5106965
    Abstract: The present invention relates to DNA and proteins of human adenovirus Type 41 and their use in detection of said virus. More specifically, the present invention relates to the isolation of a 41.4 kd short fiber protein and a 60.6 kd long fiber protein of adenovirus type 41 (Ad41), as well as proteins derived from the Ad41 E3 region, thereby providing virus-derived antigens and active derivatives and parts thereof, useful in the development of diagnostic assays, DNA probes and vaccines for said virus or other related viruses belonging to the human enteric adenovirus family. In addition, the present invention is directed to recombinant DNA molecules containing the human enteric adenovirus Type 41 Tak long fiber protein gene, the Ad41 short fiber protein gene and the Ad41 E3 gene (encoding the Ad41 proteins RL-1 to RL-6) thereby providing a source of recombinant viral components useful in the development of said diagnostic assays, DNA probes and vaccines for human adenoviruses.
    Type: Grant
    Filed: April 9, 1990
    Date of Patent: April 21, 1992
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Norman J. Pieniazek, Susan B. Slemenda, Danuta Pieniazek, Jorge Velarde, Jr., Ronald B. Luftig